Medical treatment of cushing's disease with pasireotide

European Endocrinology

Volumn 8, Issue 2, 2012, Pages 99-104

  Lacroix, André ^a   Pivonello, Rosario ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ACTH; Corticotroph tumour; Cushing's disease; Pasireotide; Somatostatin receptors

Indexed keywords

CABERGOLINE; CORTICOTROPIN; DOPAMINE 2 RECEPTOR; ETOMIDATE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; KETOCONAZOLE; LIRAGLUTIDE; METYRAPONE; MIFEPRISTONE; MITOTANE; PASIREOTIDE; RETINOIC ACID; SOMATOSTATIN RECEPTOR; STEROID 11BETA MONOOXYGENASE; VILDAGLIPTIN;

ABDOMINAL PAIN; ACNE; ACTH SECRETING ADENOMA; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; CHOLELITHIASIS; CUSHING DISEASE; DIARRHEA; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HIRSUTISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; LIVER TOXICITY; MEDICAL DECISION MAKING; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; REMISSION; SEDATION; SIDE EFFECT; TERATOGENICITY; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE; TUMOR VOLUME; UNITED STATES; VALVULAR HEART DISEASE;

EID: 84872781330     PISSN: 17583772     EISSN: 17583780     Source Type: Journal    
DOI: 10.17925/ee.2012.08.02.99     Document Type: Article

References (50)

1. Tritos NA, Biller BM, Swearingen B, Management of Cushing disease, Nat Rev Endocrinol, 2011;7:279-89
2. Boscaro M, Barzon L, Fallo F, et al., Cushing's syndrome, Lancet, 2001;357:783-91.
3. Etxabe J, Vazquez JA, Morbidity and mortality in Cushing's disease: an epidemiological approach, Clin Endocrinol (Oxf), 1994;40:479-84
4. Lindholm J, Juul S, Jorgensen JO, et al., Incidence and late prognosis of cushing's syndrome: a population-based study, J Clin Endocrinol Metab, 2001;86:117-23.
5. Pivonello R, De Martino MC, De Leo M, et al., Cushing's syndrome, Endocrinol Metab Clin North Am, 2008;37:135-49, ix.
6. Mancini T, Kola B, Mantero F, et al., High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines, Clin Endocrinol (Oxf), 2004;61:768-77.
7. Clayton RN, Raskauskiene D, Reulen RC, et al., Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature, J Clin Endocrinol Metab, 2011;96:632-42.
8. Biller BM, Grossman AB, Stewart PM, et al., Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement, J Clin Endocrinol Metab, 2008;93:2454-62.
9. Patil CG, Prevedello DM, Lad SP, et al., Late recurrences of Cushing's disease after initial successful transsphenoidal surgery, J Clin Endocrinol Metab, 2008;93:358-62.
10. Atkinson AB, Kennedy A, Wiggam MI, et al., Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance, Clin Endocrinol (Oxf), 2005;63:549-59.
11. Patil CG, Veeravagu A, Prevedello DM, et al., Outcomes after repeat transsphenoidal surgery for recurrent Cushing's disease, Neurosurgery, 2008;63:266-70; discussion 70-1.
12. Mancini T, Porcelli T, Giustina A, Treatment of Cushing disease: overview and recent findings, Ther Clin Risk Manag, 2010;6:505-16
13. Castinetti F, Morange I, Jaquet P, et al., Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease, Eur J Endocrinol, 2008;158:91-9.
14. Clinicaltrials.gov # NCT01331239, Safety and Efficacy of LCI699 in Cushing's Disease Patients. Available at: http://clinicaltrials.gov/ct2/show/NCT01331239?term= LCI699&rank=3 (accessed 5 November 2012).
15. Pivonello R, Fleseriu M, Guignat L, et al., Patients with Cushing disease achieve normal urinary cortisol with LCI699, a potent 11b-hydroxylase inhibitor: Preliminary results from a multicenter, proof-of-concept study, Endocr Rev, 2012;33:OR49-1.
16. Baudry C, Coste J, Bou Khalil R, et al., Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center, Eur J Endocrinol, 2012;167:473-81.
17. Luton JP, Mahoudeau JA, Bouchard P, et al., Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases, N Engl J Med, 1979;300:459-64.
18. Fleseriu M, Biller BM, Findling JW, et al., Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome, J Clin Endocrinol Metab, 2012;97:2039-49.
19. Klibanski A, Clinical practice. Prolactinomas, N Engl J Med, 2010;362:1219-26.
20. Pivonello R, Ferone D, de Herder WW, et al., Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors, J Clin Endocrinol Metab, 2004;89:4493-502.
21. Lila AR, Gopal RA, Acharya SV, et al., Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy, Endocr Pract, 2010;16:968-76.
22. Pivonello R, De Martino MC, Cappabianca P, et al., The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery, J Clin Endocrinol Metab, 2009;94:223-30.
23. Vilar L, Naves LA, Azevedo MF, et al., Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease, Pituitary, 2010;13:123-9.
24. Godbout A, Manavela M, Danilowicz K, et al., Cabergoline monotherapy in the long-term treatment of Cushing's disease, Eur J Endocrinol, 2010;163:709-16.
25. Pecori Giraldi F, Ambrogio AG, Andrioli M, et al., Potential role for retinoic acid in patients with Cushing's disease, J Clin Endocrinol Metab, 2012;97:3577-83.
26. Hofland LJ, van der Hoek J, Feelders R, et al., The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5, Eur J Endocrinol, 2005;152:645-54.
27. Boscaro M, Ludlam WH, Atkinson B, et al., Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial, J Clin Endocrinol Metab, 2009;94:115-22.
28. Pedroncelli AM, Medical treatment of Cushing's disease: somatostatin analogues and pasireotide, Neuroendocrinology, 2010;92(Suppl. 1):120-4.
29. EMA, Orphan designation (EU/3/09/671): pasreotide for the treatment of Cushing's disease, Electronic Source, 2009. Available at: www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/orphans/2009/11/human_ orphan_000677.jsp&mid=WC0b01ac058001d12b (accessed 5 November 2012).
30. Colao A, Petersenn S, Newell-Price J, et al., Pasireotide in Cushing's disease - Results from a 12-month phase III study, N Engl J Med, 2012;366:914-24.
31. Henry RR, Mudaliar S, Wetli-Hermosillo K, et al., Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers, presented at the 13th European Congress of Endocrinology 2011, 30 April - 4 May 2011, Rotterdam, The Netherlands, Endocrine Abstracts, 2011;26:P260.
32. Bertherat J, Ludlam W, Pivonello R, et al., Long-term use of pasireotide in Cushing's disease: 24-month safety results from a randomized Phase III study, Presented at the 14th European Congress of Endocrinology 2012, 5-9 May 2012, Florence, Italy, Endocrine Abstracts, 2012;29:P1405.
33. Pivonello R, van Gaal L, Salgado LR, et al., Long-term use of pasireotide results in sustained reductions in UFC and continued improvements in signs and symptoms in patients with Cushing's disease, presented at the 15th Congress of the European Neuroendocrine Association, 12-15 September 2012, Vienna, Austria, Abstract OC05.
34. Libe R, Groussin L, Bertherat J, Pasireotide in Cushing's disease, N Engl J Med, 2012;366:2134; author reply -5
35. Lacroix A, Ludlam W, Mantero F, et al., Initial response to pasireotide treatment is predictive of 12-month response: Results of a large, randomized, double-blind, phase III study in patients with Cushing disease, presented at the 94th Annual Meeting of Endocrine Society, 2012, Houston TX, US, Endocr Rev, Vol 33 (03_MeetingAbstracts): OR49-2.
36. Feelders RA, de Bruin C, Pereira AM, et al., Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease, N Engl J Med, 2010;362:1846-8.
37. Pasireotide - SmPC, Pasireotide - Summary of product characteristics. Available at: www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/ 002052/WC500128056.pdf (accessed 20 September 2012).
38. Clinicaltrials.gov #NCT01374906, Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease. Available at: http://clinicaltrials.gov/show/ NCT01374906 (accessed 20 September 2012).
39. Rees DA, Hanna FW, Davies JS, et al., Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission, Clin Endocrinol (Oxf), 2002;56:541-51.
40. Hammer GD, Tyrrell JB, Lamborn KR, et al., Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results, J Clin Endocrinol Metab, 2004;89:6348-57.
41. Bochicchio D, Losa M, Buchfelder M, Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group, J Clin Endocrinol Metab, 1995;80:3114-20
42. Yap LB, Turner HE, Adams CB, et al., Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit, Clin Endocrinol (Oxf), 2002;56:25-31.
43. Chee GH, Mathias DB, James RA, et al., Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome?, Clin Endocrinol (Oxf), 2001;54:617-26.
44. van Aken MO, de Herder WW, van der Lely AJ, et al., Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease, Clin Endocrinol (Oxf), 1997;47:145-9.
45. Thoren M, Adamson U, Sjoberg HE, Aminoglutethimide and metyrapone in the management of Cushing's syndrome, Acta Endocrinol (Copenh), 1985;109:451-7
46. Verhelst JA, Trainer PJ, Howlett TA, et al., Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome, Clin Endocrinol (Oxf), 1991;35:169-78.
47. Preda VA, Sen J, Karavitaki N, et al., Etomidate in the management of hypercortisolaemia in Cushing's syndrome, Eur J Endocrinol, 2012;167:137-43.
48. Castinetti F, Fassnacht M, Johanssen S, et al., Merits and pitfalls of mifepristone in Cushing's syndrome, Eur J Endocrinol, 2009;160:1003-10.
49. Bertagna X, Bertagna C, Laudat MH, et al., Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome, J Clin Endocrinol Metab, 1986;63:639-43.
50. Schade R, Andersohn F, Suissa S, et al., Dopamine agonists and the risk of cardiac-valve regurgitation, N Engl J Med, 2007;356:29-38.